Total triiodothyronine (T3) or free T3 and free thyroxine (T4) are within normal limits. (control by thyroid replacement therapy is acceptable.) Participants with T3, free T3 or free T4 abnormalities at screening who are asymptomatic can be eligible
History of other malignancy unless the subject has been disease-free for at least 3 years
History of prior malignancy unless disease free for > or equal to 12 months or considered surgically cured.
Any other cancer, unless the patient has been disease-free for ?5 years
Willing to be smoke-free for 7 days
Clinically disease-free after surgery
Disease-free interval =< 30 months
have had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing treatment OR
Prior invasive malignancy (except non-melanoma skin cancer), unless disease-free for at least 3 years; no patient with a history of pelvic or hematologic malignancy is eligible, regardless of disease-free interval
Patients who have a history of another primary malignancy unless the patient has been disease free for >= 3 years
Thyroid Function: Total T3 or free T3, total T4 or free T4 and THS ? CTCAE Grade 2 abnormality.
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Previous diagnosis of invasive cancer from which the individual is NOT disease-free AND that has required treatment within the past 5 years, except for superficial skin, cervical cancer in-situ, well-differentiated thyroid or early stage prostate or bladder cancer (i.e., treatment with curative intent and long term disease-free expectations)
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Previous diagnosis of invasive cancer from which the individual is NOT disease-free AND that has required treatment within the past 5 years, except for superficial skin, cervical cancer in-situ, well-differentiated thyroid or early stage prostate or bladder cancer (i.e., treatment with curative intent and long term disease-free expectations)
Have a prior history of cancer other than MDS or myeloproliferative disorder, unless the subject has been free of the disease for ? 1 year prior to the start of study treatment.
Must have disease free status as determined by imaging within 4 weeks of dosing
History of another malignancy, unless the candidate has been disease-free for at least 5 years.
Previous diagnosis of invasive cancer from which the individual is NOT disease-free AND that has required treatment within the past 5 years, except for superficial skin, cervical cancer in-situ, well-differentiated thyroid or early stage prostate or bladder cancer (i.e., treatment with curative intent and long term disease-free expectations).
Patient has EITHER:\r\n* A Kattan nomogram predicted probability of being disease free 5 years after surgery of < 60%, OR\r\n* A Gleason sum >= 8
Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment and are considered free of disease
Patients who have been continuously disease-free for any solid tumor malignancy >3 years prior to the time of enrollment.
Similar condition with an expectation of > 95% five-year disease-free survival
Patients with a previous malignancy (other than the patients' known cancer) that were treated successfully and are disease-free for at least 3 years are allowed
Any other cancer from which the patient has been disease-free for 5 years
Disease-free
Any other cancer from which the subject has been disease-free for ?2 years
Any other cancer from which the subject has been disease-free for ?3 years
History of another malignancy in the previous 5 years, unless cured by surgery alone and continuously disease-free
Free of metastatic malignancy (other than MDS) for ?2 years
Eligible patients must be considered disease-free or have stable disease
Free of macro-metastatic disease
Free from significant psychiatric history
NON-CANCER PATIENT GROUP: Cancer-free
Be considered disease-free at baseline
Clinically cancer-free (no evidence of disease)
If patients have a history of malignancy other than melanoma or malignant brain tumor they must be disease-free (excluding primary cancer for metastatic patients) for >= 5 years at the time of enrollment
History of any malignancy (excluding primary cancer for metastatic patients) other than melanoma or malignant brain tumors for which the disease-free interval is < 5 years
Any other cancer from which the subject has been disease free for 3 years